Literature DB >> 12000789

Nf2 gene inactivation in arachnoidal cells is rate-limiting for meningioma development in the mouse.

Michel Kalamarides1, Michiko Niwa-Kawakita, Hélène Leblois, Vincent Abramowski, Michel Perricaudet, Anne Janin, Gilles Thomas, David H Gutmann, Marco Giovannini.   

Abstract

Biallelic NF2 gene inactivation is common in sporadic and in neurofibromatosis type 2 (NF2)-related meningiomas. We show that, beginning at four months of age, thirty percent of mice with arachnoidal cell Cre-mediated excision of Nf2 exon 2 developed a range of meningioma subtypes histologically similar to the human tumors. Additional hemizygosity for p53 did not modify meningioma frequency or progression suggesting that Nf2 and p53 mutations do not synergize in meningeal tumorigenesis. This first mouse model initiated with a genetic lesion found in human meningiomas provides a powerful tool for investigating tumor progression and for the preclinical evaluation of therapeutic interventions.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12000789      PMCID: PMC186259          DOI: 10.1101/gad.226302

Source DB:  PubMed          Journal:  Genes Dev        ISSN: 0890-9369            Impact factor:   11.361


  22 in total

1.  Loss of merlin expression in sporadic meningiomas, ependymomas and schwannomas.

Authors:  D H Gutmann; M J Giordano; A S Fishback; A Guha
Journal:  Neurology       Date:  1997-07       Impact factor: 9.910

2.  Rapid colorectal adenoma formation initiated by conditional targeting of the Apc gene.

Authors:  H Shibata; K Toyama; H Shioya; M Ito; M Hirota; S Hasegawa; H Matsumoto; H Takano; T Akiyama; K Toyoshima; R Kanamaru; Y Kanegae; I Saito; Y Nakamura; K Shiba; T Noda
Journal:  Science       Date:  1997-10-03       Impact factor: 47.728

3.  Widespread long-term gene transfer to mouse skeletal muscles and heart.

Authors:  L D Stratford-Perricaudet; I Makeh; M Perricaudet; P Briand
Journal:  J Clin Invest       Date:  1992-08       Impact factor: 14.808

4.  Expression patterns of the p53 tumor suppressor gene and the mdm2 proto-oncogene in human meningiomas.

Authors:  M J Pykett; J Landers; D L George
Journal:  J Neurooncol       Date:  1997-03       Impact factor: 4.130

5.  Targeted DNA recombination in vivo using an adenovirus carrying the cre recombinase gene.

Authors:  Y Wang; L A Krushel; G M Edelman
Journal:  Proc Natl Acad Sci U S A       Date:  1996-04-30       Impact factor: 11.205

6.  Mice heterozygous for a mutation at the Nf2 tumor suppressor locus develop a range of highly metastatic tumors.

Authors:  A I McClatchey; I Saotome; K Mercer; D Crowley; J F Gusella; R T Bronson; T Jacks
Journal:  Genes Dev       Date:  1998-04-15       Impact factor: 11.361

Review 7.  Meningioangiomatosis is associated with neurofibromatosis 2 but not with somatic alterations of the NF2 gene.

Authors:  A O Stemmer-Rachamimov; M A Horgan; A L Taratuto; D G Munoz; T W Smith; M P Frosch; D N Louis
Journal:  J Neuropathol Exp Neurol       Date:  1997-05       Impact factor: 3.685

8.  A genetic study of type 2 neurofibromatosis in the United Kingdom. II. Guidelines for genetic counselling.

Authors:  D G Evans; S M Huson; D Donnai; W Neary; V Blair; V Newton; T Strachan; R Harris
Journal:  J Med Genet       Date:  1992-12       Impact factor: 6.318

9.  Genetic background alters the spectrum of tumors that develop in p53-deficient mice.

Authors:  M Harvey; M J McArthur; C A Montgomery; A Bradley; L A Donehower
Journal:  FASEB J       Date:  1993-07       Impact factor: 5.191

10.  The impact of developmental stage, route of administration and the immune system on adenovirus-mediated gene transfer.

Authors:  A Kass-Eisler; E Falck-Pedersen; D H Elfenbein; M Alvira; P M Buttrick; L A Leinwand
Journal:  Gene Ther       Date:  1994-11       Impact factor: 5.250

View more
  63 in total

Review 1.  Brain tumours: classification and genes.

Authors:  V P Collins
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-06       Impact factor: 10.154

Review 2.  Merlin: a tumour suppressor with functions at the cell cortex and in the nucleus.

Authors:  Wei Li; Jonathan Cooper; Matthias A Karajannis; Filippo G Giancotti
Journal:  EMBO Rep       Date:  2012-03       Impact factor: 8.807

Review 3.  Mouse models of inherited cancer syndromes.

Authors:  Sohail Jahid; Steven Lipkin
Journal:  Hematol Oncol Clin North Am       Date:  2010-12       Impact factor: 3.722

4.  Maternally expressed gene 3, an imprinted noncoding RNA gene, is associated with meningioma pathogenesis and progression.

Authors:  Xun Zhang; Roger Gejman; Ali Mahta; Ying Zhong; Kimberley A Rice; Yunli Zhou; Pornsuk Cheunsuchon; David N Louis; Anne Klibanski
Journal:  Cancer Res       Date:  2010-02-23       Impact factor: 12.701

5.  Jagged1 signals in the postnatal subventricular zone are required for neural stem cell self-renewal.

Authors:  Yves Nyfeler; Robert D Kirch; Ned Mantei; Dino P Leone; Freddy Radtke; Ueli Suter; Verdon Taylor
Journal:  EMBO J       Date:  2005-09-15       Impact factor: 11.598

Review 6.  Harnessing preclinical mouse models to inform human clinical cancer trials.

Authors:  David H Gutmann; Kim Hunter-Schaedle; Kevin M Shannon
Journal:  J Clin Invest       Date:  2006-04       Impact factor: 14.808

7.  Molecular and translational advances in meningiomas.

Authors:  Suganth Suppiah; Farshad Nassiri; Wenya Linda Bi; Ian F Dunn; Clemens Oliver Hanemann; Craig M Horbinski; Rintaro Hashizume; Charles David James; Christian Mawrin; Houtan Noushmehr; Arie Perry; Felix Sahm; Andrew Sloan; Andreas Von Deimling; Patrick Y Wen; Kenneth Aldape; Gelareh Zadeh
Journal:  Neuro Oncol       Date:  2019-01-14       Impact factor: 12.300

Review 8.  Neurofibromatosis-related tumors: emerging biology and therapies.

Authors:  Matthias A Karajannis; Rosalie E Ferner
Journal:  Curr Opin Pediatr       Date:  2015-02       Impact factor: 2.856

9.  The neurofibromatosis 2 tumor suppressor gene product, merlin, regulates human meningioma cell growth by signaling through YAP.

Authors:  Katherine Striedinger; Scott R VandenBerg; Gilson S Baia; Michael W McDermott; David H Gutmann; Anita Lal
Journal:  Neoplasia       Date:  2008-11       Impact factor: 5.715

10.  What's new in neurofibromatosis? Proceedings from the 2009 NF Conference: new frontiers.

Authors:  Joseph L Kissil; Jaishri O Blakeley; Rosalie E Ferner; Susan M Huson; Michel Kalamarides; Victor-Felix Mautner; Frank McCormick; Helen Morrison; Roger Packer; Vijaya Ramesh; Nancy Ratner; Katherine A Rauen; David A Stevenson; Kim Hunter-Schaedle; Kathryn North
Journal:  Am J Med Genet A       Date:  2010-02       Impact factor: 2.802

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.